A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 107
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EC
Long Form : endocannabinoid
No. Year Title Co-occurring Abbreviation
2004 Involvement of cannabinoid receptors in gut motility and visceral perception. CBRs
2005 Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. AS, CA, DLPFC
2005 The endocannabinoid system: a new approach to control cardiovascular disease. CB1, CB2
2006 Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol. EtOH
2006 Role of the endocannabinoid system in depression and suicide. ---
2006 The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. FAAH
2007 CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. ---
2007 Endocannabinoids and cardiovascular prevention: real progress? ---
2007 Endocannabinoids and neurodegenerative diseases. AD, AEA, FAAH, HD, ML, MS
10  2007 Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. 2-AG, 2-LG, AEA, HEA, OEA, PEA, SPE
11  2007 Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. CB1, GI
12  2007 The endocannabinoid system in the regulation of cardiometabolic risk factors. ---
13  2007 The endocannabinoid system: a new target for the regulation of energy balance and metabolism. ---
14  2007 The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. CVD
15  2007 [Pharmacology of cannabinoid receptors]. ---
16  2008 A human fatty acid amide hydrolase (FAAH) functional gene variant is associated with lower blood pressure in young males. BP, ECS, FAAH, YM
17  2008 Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. CB1Rs, EPSCs, mEPSC
18  2008 Cat odour-induced anxiety--a study of the involvement of the endocannabinoid system. PAG
19  2008 Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. 2-AG, AEA, HFDs
20  2008 Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. apo, CB1, IDFP, TG
21  2008 Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. CD, FAAH, mRNA
22  2008 The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. AN, CBD, FAAH, VEH
23  2008 The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. AEA, DIO
24  2009 Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission. CB1R, DMNV, DSE, DSI, DVC, eIPSCs
25  2009 Feeding disorders and obesity. CB1
26  2009 Plasma endocannabinoid levels in multiple sclerosis. AEA, FAAH, MS, PEA, PP, RR, SP
27  2009 Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding. CB1, HF
28  2009 The endocannabinoid system: a promising target for the management of type 2 diabetes. ---
29  2010 Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. AMPK, CB1R, PGC-1alpha, siRNA, UCP1
30  2010 Endocannabinoid (EC) receptor, CB1, and EC enzymes' expression in primary adipocyte cultures of lean and obese pre-pubertal children in relation to adiponectin and insulin. Ad, EE, IR, PP, Pr
31  2010 Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. CB1R, MET-F-AEA
32  2010 The endocannabinoid 2-arachidonoylglycerol (2-AG) and metabolizing enzymes during rat fetoplacental development: a role in uterine remodelling. 2-AG
33  2010 The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. PUFA
34  2011 Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. ACEA, WIN
35  2011 Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells. AA, AEA, ALP, CB2, DHA, EPA, FAAH, NAPE-PLD, OA, PUFA
36  2011 Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. 2-AG, AEA, CPT, MBF
37  2011 Endocannabinoid signaling and energy metabolism: a target for dietary intervention. ---
38  2011 Endocannabinoid system dysfunction in mood and related disorders. CB1, CBD, CNR1, THC
39  2011 New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. ---
40  2012 A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. CB1
41  2012 Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. 2-AG, AEA, CB1
42  2012 Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2-AG, AA, AEA, EPA, HS, PUFA, WB
43  2012 Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. AEA, CB, FAAH, FAEs, GI
44  2012 Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. apoA-I, CBR1, HDL-C
45  2012 Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. AEA, CBs, CRC
46  2012 Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: association with wrist cutting as impulsive self-injurious behavior. AN, BDI, BN, CB1, EDs, HCW, SIB
47  2012 Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. DA, NT, VTA
48  2012 NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression. 2-AG, CB1Rs, CHPG, DHPG, LFS, LTD, mGluR5, NLDE, NMDAR
49  2012 Peripheral endocannabinoid microdialysis: in vitro characterization and proof-of-concept in human subjects. 2-AG, AEA, HPCD, HSA
50  2012 Rimonabant, gastrointestinal motility and obesity. GI
51  2012 Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. 1AG, 2-AG
52  2013 Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. 2-AG, AEA, CSF
53  2013 Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link? MAP, PI3K
54  2013 Endocannabinoid system as a potential mechanism for n-3 long-chain polyunsaturated fatty acid mediated cardiovascular protection. LC
55  2013 The role of endocannabinoids system in fatty liver disease and therapeutic potentials. CB1, NAFLD
56  2014 Alterations in the anandamide metabolism in the development of neuropathic pain. AEA, CCI, DRGs
57  2014 Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. 2-AG, AEA, AN, FAAH, LiCl, MAGL, VEH
58  2014 Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity. 2-AG, AEA, CB, COX, DAGL, DHA, DHEA, ECS
59  2014 Endocannabinoid modulation of cortical up-states and NREM sleep. CB1, KO
60  2014 Endocannabinoid system and pain: an introduction. AEA, CNS
61  2014 Impact of obesity and bariatric surgery on metabolism and coronary circulatory function. PET
62  2014 The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. CB1, e.j.p, GI, IJP
63  2014 The endocannabinoid system: directing eating behavior and macronutrient metabolism. ECS, PUFA
64  2015 CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Delta9-tetrahydrocannabinol. 2-AG, EGC, WT
65  2015 Diacylglycerol Lipase alpha Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice. 2-AG, BW, CNR1, KOs, WT
66  2015 Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. 2-AG, AEA, CHC, FAAH, HCV, HSC, MAGL, PBMC
67  2015 Endocannabinoid regulation of amyloid-induced neuroinflammation. AD, FAAH
68  2015 Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. 2-AG, AEA, FAAH, HC, OEA, PEA
69  2015 Oleic acid content of a meal promotes oleoylethanolamide response and reduces subsequent energy intake in humans. HOSO, OEA, SO, VOO
70  2015 The role of the endocannabinoid system in pain. 2-AG, AEA, ECs
71  2016 Anandamide mediates cognitive judgement bias in rats. ACI, AEA, CB1, CB2
72  2016 Association between plasma endocannabinoids and appetite in hemodialysis patients: A pilot study. DHEA, LEA, PUFA, SNAQ
73  2016 Cannabinoid receptor signaling regulates liver development and metabolism. CNR, CNR1
74  2016 FABP-1 gene ablation impacts brain endocannabinoid system in male mice. 2-AG, AEA, FABP-1, OEA, WT
75  2016 Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels. 2-AG, 2-OG, AEA, ARA
76  2016 Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury. 2-AG, AKI, BUN, IRI
77  2016 Microencapsulated bitter compounds (from Gentiana lutea) reduce daily energy intakes in humans. CP, EBI, NAE
78  2016 Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet. 2-AG, AEA, HFD, MD, OEA, PEA
79  2017 Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia. ABA, AN
80  2017 Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. 2-AG
81  2017 Endocannabinoid concentrations in plasma during the finishing period are associated with feed efficiency and carcass composition of beef cattle. 2-AG, AEA, DOS, RFI
82  2017 Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability. 2-AG, mEPSC, mTBI, TBI
83  2017 Inhibitors of oxidative and hydrolytic endocannabinoid degradation do not enhance depolarization-induced suppression of excitation on dorsal cochlear nucleus glycinergic neurons. COX-2, DCN, DSE, PF-CW
84  2017 Insulin induces a shift in lipid and primary carbon metabolites in a model of fasting-induced insulin resistance. aa, FFA, NES, PCM
85  2017 Loss of fatty acid binding protein-1 alters the hepatic endocannabinoid system response to a high-fat diet. AEA, CB1, Fabp1, FTM, HFD, NAFLD
86  2017 Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. CPT, MBF, MOB, OEA, PEA, VCAM-1
87  2017 Regulation of fear extinction by long-term depression: The roles of endocannabinoids and brain derived neurotrophic factor. BDNF, PTSD
88  2017 The cannabinoid system and pain. mPFC
89  2017 The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. ASD
90  2018 Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. 1-AG, CM, OEA, PEA, SEA
91  2018 Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. AEA, AraS, EC-like, MRSA
92  2018 Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. SB
93  2018 Circulating endocannabinoids and affect regulation in human subjects. 2-AG, AEA
94  2018 Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. CBRs, FAAH, MAGL
95  2018 Endocannabinoid Signaling at Hypothalamic Steroidogenic Factor-1/Proopiomelanocortin Synapses Is Sex- and Diet-Sensitive. DSE, eEPSCs, HFD, POMC, SF, VMN
96  2018 Endocrine disruptors in the diet of male Sparus aurata: Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. AEA, BPA, DINP, ECS, EDC, NPY
97  2018 Enhancement of Endocannabinoid-dependent Depolarization-induced Suppression of Excitation in Glycinergic Neurons by Prolonged Exposure to High Doses of Salicylate. DCN, DSE
98  2018 Human Liver Fatty Acid Binding Protein-1 T94A Variant, Nonalcohol Fatty Liver Disease, and Hepatic Endocannabinoid System. 2-MAG, AEA, CB1, FABP1, WT
99  2018 Impact of Fabp1 Gene Ablation on Uptake and Degradation of Endocannabinoids in Mouse Hepatocytes. 2-AG, AEA, ARA
100  2018 Oxidative burst and Dectin-1-triggered phagocytosis affected by norepinephrine and endocannabinoids: implications for fungal clearance under stress. AR, mTOR, NE, PMNs, ROS
101  2018 Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. DM, DN
102  2018 Role of Nitric Oxide in the Cardiovascular and Renal Systems. EDRF, NO
103  2018 Salivary endocannabinoids and N-acylethanolamines upon mastication of a semisolid food: implications in fat taste, appetite and food liking. MSF, NAE
104  2018 Scp-2/Scp-x ablation in Fabp1 null mice differentially impacts hepatic endocannabinoid level depending on dietary fat. 2-AG, AEA, ARA, HFD, SCP-2
105  2018 Signaling pathways to and from the hypophysial pars tuberalis, an important center for the control of seasonal rhythms. 2-AG, MBH, PT
106  2018 Structural and Functional Interaction of Delta9-Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). CD, Delta9-THC, NBD-AEA, WT
107  2018 The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. 2-AG, AEA, FAAH